Serum gamma glutamyl transpeptidase in breast cancer

Abstract

Gamma-glutamyl transpeptidase (gamma-GT) levels were estimated in the sera of patients with breast cancer and compared with those of benign breast diseases and healthy controls. Serum gamma-GT levels were found to be significantly increased in patients with breast cancer compared to the controls as well as benign breast diseases. The rise however, was nearly same in all the patients irrespective of histopathology of cancer but was directly related to tumour mass. After mastectomy the levels remained higher upto 3 months. In patients with cancer the rise in serum gamma-GT was significantly higher as compared to those with benign breast diseases. Although gamma-GT is an index of liver diseases, its high level in breast carcinoma suggests the release of the membrane bound constituents from different tissues even in carcinoma.